ABT vs TARS · P/E 25, rev $44.33B vs rev $336.0M
Abbott Laboratories (ABT) versus Tarsus Pharmaceuticals Inc (TARS) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Tarsus Pharmaceuticals Inc (TARS) is a biotechnology company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported TARS revenue for 2026-06-30 was $336.0M. Net income was -$25.5M. TARS currently screens at market cap $2.66B.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. TARS currently screens at market cap $2.66B.
Not investment advice. Open the ABT and TARS stock pages for the full models.
Not investment advice.